Disclosure under regulation 29(2) of SEBI(SAST)Regulations, 2011 received from Ishita Pharmaceuticals, related party of Ishita Drugs and Industries Limited.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Pharmaceuticals, a related party of Ishita Drugs & Industries Ltd, has acquired 506 equity shares of Rs. 10 each from the open market on February 24, 2026. The acquisition is negligible in size, representing just 0.02% of the company's paid-up equity capital. With this purchase, Ishita Pharmaceuticals' holding in Ishita Drugs has marginally increased from 31,746 shares (1.06%) to 32,252 shares (1.08%). The total equity share capital of the company remains unchanged at Rs. 2,99,03,000 (29,90,300 shares of Rs. 10 each). The disclosure is filed by the company based on information received from the related party acquirer.
This is a routine, minor open-market purchase by a related party with no material impact on shareholding structure or control. Shareholders are unlikely to see any meaningful effect on the stock from this 0.02% incremental acquisition.